|Mr. Frank R. Oakes||Chairman, Pres & CEO||429.84k||N/A||1950|
|Ms. Kathi Niffenegger CPA||CFO & Corp. Sec.||262.81k||N/A||1957|
|Dr. Gregory T. Baxter||Exec. VP of Corp. Devel.||N/A||N/A||1959|
|Mr. Gary Koppenjan||Sr. Director of Investor Relations & Communications||N/A||N/A||N/A|
|Brando Lincicum||Exec. Director of Aquaculture and Facility Operations||N/A||N/A||N/A|
Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.
Stellar Biotechnologies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.